These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7560811)

  • 1. Simple and reliable method for predicting the remission of Graves' disease: revised triiodothyronine-suppression test, indexed by serum thyroxine.
    Takasu N; Akamine H; Komiya I; Yamada T
    J Endocrinol Invest; 1995 Apr; 18(4):288-94. PubMed ID: 7560811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reappraisal of the 3,5,3'-triiodothyronine-suppression test in the prediction of long term outcome of antithyroid drug therapy in patients with hyperthyroid Graves' disease.
    Yamada T; Koizumi Y; Sato A; Hashizume K; Aizawa T; Takasu N; Nagata H
    J Clin Endocrinol Metab; 1984 Apr; 58(4):676-80. PubMed ID: 6421866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients.
    Tamai H; Hayaki I; Kawai K; Komaki G; Matsubayashi S; Kuma K; Kumagai LF; Nagataki S
    J Clin Endocrinol Metab; 1995 May; 80(5):1481-4. PubMed ID: 7744989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ratio of serum triiodothyronine to thyroxine and the prognosis of triiodothyronine-predominant Graves' disease.
    Takamatsu J; Sugawara M; Kuma K; Kobayashi A; Matsuzuka F; Mozai T; Hershman JM
    Ann Intern Med; 1984 Mar; 100(3):372-5. PubMed ID: 6546484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T4 suppression test involving 24-hour thyroidal 131I uptake in patients with Graves' disease compared to the T3 suppression test.
    Kobayashi I; Ishii H; Mori M; Kobayashi S
    Endocrinol Jpn; 1984 Jun; 31(3):263-70. PubMed ID: 6548699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves' disease.
    Roti E; Minelli R; Gardini E; Bianconi L; Salvi M; Gavaruzzi G; Ugolotti G; Braverman LE
    J Clin Endocrinol Metab; 1994 Mar; 78(3):795-9. PubMed ID: 8126159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis.
    Sato A; Yamada T; Aizawa T; Ichikawa K; Komiya I; Takasu N; Takemura Y
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2173-7. PubMed ID: 7608274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum thyroglobulin concentration as an indicator for assessing thyroid stimulation in patients with Graves' disease during antithyroid drug therapy.
    Aizawa T; Ishihara M; Koizumi Y; Hashizume K; Takasu N; Yamada T; Kobayashi I; Watanabe T; Shimizu Z
    Am J Med; 1990 Aug; 89(2):175-80. PubMed ID: 2166430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves' hyperthyroidism.
    Andrade VA; Gross JL; Maia AL
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4012-6. PubMed ID: 10566642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum thyroid-stimulating antibody, thyroglobulin levels, and thyroid suppressibility measurement as predictors of the outcome of combined methimazole and triiodothyronine therapy in Graves' disease.
    Werner RS; Romaldini JH; Farah CS; Werner MC; Bromberg N
    Thyroid; 1991; 1(4):293-9. PubMed ID: 1688155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
    Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
    J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pituitary-thyroid feedback regulation in patients with Graves' disease during antithyroid drug therapy.
    Yamada T; Takasu N; Sato A; Aizawa T; Koizumi Y
    J Clin Endocrinol Metab; 1982 Jan; 54(1):83-8. PubMed ID: 6798061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
    Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroidal triiodothyronine and thyroxine in Graves' disease: correlation with presurgical treatment, thyroid status, and iodine content.
    Larsen PR
    J Clin Endocrinol Metab; 1975 Dec; 41(06):1098-104. PubMed ID: 54364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroidal response to an increase or decrease of endogenous TSH in patients with hyperthyroidism and its correlation with TSH binding inhibiting immunoglobulin.
    Katakura M; Koizumi Y; Aizawa T; Takasu N; Yamada T; Yukimura Y; Nagata H
    Clin Exp Pharmacol Physiol; 1986 May; 13(5):407-15. PubMed ID: 2874908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The change in 123I-uptake between 3- and 24-hours is useful in predicting early response to methimazole in patients with Graves' disease.
    Gemma R; Nakamura H; Mori T; Andoh S; Suzuki Y; Yoshimi T
    Endocr J; 1996 Feb; 43(1):61-6. PubMed ID: 8732453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Studies on the TRH test on the patients with Graves' disease during the treatment with antithyroid drug (author's transl)].
    Enomoto K; Inoue K; Enomoto H
    Nihon Naibunpi Gakkai Zasshi; 1975 Dec; 51(12):1052-64. PubMed ID: 823053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.